Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

A microfluidic model of hemostasis sensitive to platelet function and coagulation.

Schoeman RM, Rana K, Danes N, Lehmann M, Di Paola JA, Fogelson AL, Leiderman K, Neeves KB.

Cell Mol Bioeng. 2017 Feb;10(1):3-15. doi: 10.1007/s12195-016-0469-0. Epub 2016 Oct 24.

PMID:
28529666
2.

Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.

Boylan B, Rice AS, Neff AT, Manco-Johnson MJ, Kempton CL, Miller CH; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2016 Oct;14(10):1931-1940. doi: 10.1111/jth.13438. Epub 2016 Sep 17.

PMID:
27501440
3.

Mutations in the D'D3 region of VWF traditionally associated with type 1 VWD lead to quantitative and qualitative deficiencies of VWF.

White-Adams TC, Ng CJ, Jacobi PM, Haberichter SL, Di Paola JA.

Thromb Res. 2016 Sep;145:112-8. doi: 10.1016/j.thromres.2016.08.009. Epub 2016 Aug 10.

PMID:
27533707
4.

Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations.

Boylan B, Rice AS, De Staercke C, Eyster ME, Yaish HM, Knoll CM, Bean CJ, Miller CH; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2015 Jun;13(6):1036-42. doi: 10.1111/jth.12902. Epub 2015 May 9.

5.

Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.

Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH; Hemophilia Inhibitor Research Study Investigators; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2015 Jan;13(1):47-53. doi: 10.1111/jth.12768. Epub 2014 Dec 11.

6.

Platelets join the world of "Omics".

Boulden Warren B, Di Paola JA.

Blood. 2014 Apr 17;123(16):2446-7. doi: 10.1182/blood-2014-02-557389. No abstract available.

7.

FVIII/VWF ratio is not a reliable predictor of VWD in children.

Branchford BR, Ruegg K, Villalobos-Menuey E, Jacobson LJ, Di Paola JA, Manco-Johnson M.

Pediatr Blood Cancer. 2014 May;61(5):936-9. doi: 10.1002/pbc.24860. Epub 2013 Nov 26.

PMID:
24281894
8.

A study of prospective surveillance for inhibitors among persons with haemophilia in the United States.

Soucie JM, Miller CH, Kelly FM, Payne AB, Creary M, Bockenstedt PL, Kempton CL, Manco-Johnson MJ, Neff AT; Haemophilia Inhibitor Research Study Investigators.

Haemophilia. 2014 Mar;20(2):230-7. doi: 10.1111/hae.12302. Epub 2013 Nov 22.

9.

The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models.

Onasoga-Jarvis AA, Leiderman K, Fogelson AL, Wang M, Manco-Johnson MJ, Di Paola JA, Neeves KB.

PLoS One. 2013 Nov 13;8(11):e78732. doi: 10.1371/journal.pone.0078732. eCollection 2013.

10.

Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.

Zhang W, McIver AL, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X.

J Med Chem. 2013 Dec 12;56(23):9693-700. doi: 10.1021/jm4013888. Epub 2013 Nov 20.

11.

Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.

Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2013 Jul;11(7):1300-9. doi: 10.1111/jth.12259.

12.

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.

Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR.

Blood. 2013 May 2;121(18):3742-4. doi: 10.1182/blood-2012-12-471672. Epub 2013 Mar 21.

13.

Sources of variability in platelet accumulation on type 1 fibrillar collagen in microfluidic flow assays.

Neeves KB, Onasoga AA, Hansen RR, Lilly JJ, Venckunaite D, Sumner MB, Irish AT, Brodsky G, Manco-Johnson MJ, Di Paola JA.

PLoS One. 2013;8(1):e54680. doi: 10.1371/journal.pone.0054680. Epub 2013 Jan 23.

14.

Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.

Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2012 Jun;10(6):1055-61. doi: 10.1111/j.1538-7836.2012.04705.x.

15.

F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity.

Miller CH, Benson J, Ellingsen D, Driggers J, Payne A, Kelly FM, Soucie JM, Craig Hooper W; Hemophilia Inhibitor Research Study Investigators.

Haemophilia. 2012 May;18(3):375-82. doi: 10.1111/j.1365-2516.2011.02700.x. Epub 2011 Nov 21.

PMID:
22103590
16.

Characterization of collagen thin films for von Willebrand factor binding and platelet adhesion.

Hansen RR, Tipnis AA, White-Adams TC, Di Paola JA, Neeves KB.

Langmuir. 2011 Nov 15;27(22):13648-58. doi: 10.1021/la2023727. Epub 2011 Oct 19.

PMID:
21967679
17.

Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR.

Blood. 2010 Jul 15;116(2):280-6. doi: 10.1182/blood-2009-10-249102. Epub 2010 Mar 15.

18.

Immune thrombocytopenic purpura.

Di Paola JA, Buchanan GR.

Pediatr Clin North Am. 2002 Oct;49(5):911-28. Review.

PMID:
12430619
19.

Supplemental Content

Loading ...
Support Center